NCT02990325View on ClinicalTrials.gov

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

December 27, 2018

Study Completion Date

October 21, 2019

Conditions
HIV InfectionsHealth Volunteers
Interventions
DRUG

ABX464 150mg

ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)

DRUG

ABX464 50mg

ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)

DRUG

ABX464 50mg

ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)

Trial Locations (1)

08916

Hospital Universitari Germans Trias i Pujol, Badalona

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
lead

Abivax S.A.

INDUSTRY